This is the authors' abstract. We don't add key points for this paper.
Objectives:The need for early detection of lysosomal storage diseases (LSDs) for which therapeutic options are available makes them attractive candidate disorders to perform high-throughput population screening.This is a pilot study designed to simultaneously screen for Krabbe, Niemann-Pick types A/B, Fabry, Gaucher and Pompe diseases in putatively normal Indian subjects, using dried blood spots and a liquid chromatography-tandem mass spectrometry method.Methods: Blood spots from 12,559 putatively normal subjects were used to measure 5 lysosomal enzymes: galactocerebrosidase, acid sphingomyelinase, α-galactosidase, β-glucocerebrosidase, and α-glucosidase.From each blood spot, 3.2-mm punches were extracted and incubated using specific substrates and internal standards.After several liquid-and solid-phase extraction steps, the resulting solution was reconstituted and injected into a triple quadrupole, liquid chromatography-tandem mass spectrometer after recombining the reaction products into a single 96-well plate.Results: A standard calibration curve demonstrated good linearity for each enzyme.No positive case was detected among the 12,559 putatively normal subjects tested.Conclusion: Tandem mass spectrometry technology makes it possible to perform high-throughput screening to identify LSDs using blood spots.Further large-scale studies to determine the population prevalence and incidence of these disorders are warranted.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rita Christopher (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: